Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

The intervention being tested is Dupilumab, a drug administered via subcutaneous injection. It is intended to manage symptoms of PN, particularly the intense itching associated with the condition.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, according to a ...

One abstract reviewed results from Part A and Part C. 1 Part A was a 24-week study comparing dupilumab 300 mg vs placebo and Part C was a 28-week extended active treatment period for patients who ...

BOSTON — Dupilumab reduced exacerbations and improved lung function in children with asthma, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual ...

Meeting Coverage > ACG Dupilumab Helped Kids With Eosinophilic Esophagitis Achieve Needed Weight Gain — The drug also met primary endpoint of reducing peak esophageal intraepithelial eosinophil ...

Meeting Coverage > CHEST Biologic Dupilumab Shows Sustained Benefit in Asthma Patients — Reduced oral corticosteroid use, improved lung function maintained after nearly 2 years by Salynn Boyles ...

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and WP-NRS 0/1 at week 16. Among patients with moderate to severe atopic ...

Dupilumab (Dupixent) relieves signs and symptoms of eosinophilic esophagitis (EoE) for up to 52 weeks, researchers say. Few side effects, other than injection pain, emerged in the year-long phase ...

Dupilumab was also associated with improvements in lung function (change in pre-bronchodilator FEV 1 from baseline to week 12: 160mL vs 77mL for placebo; P <.0001) that were sustained through 52 ...

Dupilumab-Associated Ocular Surface Disease in Patients With AD: Unravelling the Link Kate Johnson October 21, 2022 0 ...